CN1209435A - Chinese trichosanthes protein, preparation method and use in pharmacy - Google Patents
Chinese trichosanthes protein, preparation method and use in pharmacy Download PDFInfo
- Publication number
- CN1209435A CN1209435A CN97115693A CN97115693A CN1209435A CN 1209435 A CN1209435 A CN 1209435A CN 97115693 A CN97115693 A CN 97115693A CN 97115693 A CN97115693 A CN 97115693A CN 1209435 A CN1209435 A CN 1209435A
- Authority
- CN
- China
- Prior art keywords
- trichobitacin
- hiv
- protein
- cell
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a new active ribosome inactivation protein capable of inhibiting HIV-trichosanic protein and its preparation method. Its crude product and pure product can obviously inhibite the formation of HIV-1 induced C8166 plasmodium, and in the acute infection, it can obviously inhibite the expression of HIV-IP24 antigen, and when said compound concentration is 0.04 microgram/ml, the antigen expression inhibition rates of 94P73CMI and 94P75CMI to P24 are respectively 54.8% and 52.6% (i.e. EC50 is less than 0.04 microgram/ml), and the HIV-1 antigen positive cell is reduced by 47.0%. In the chronic infection, the trichosanic protein does not affect the replication of HIV-1 IIIB, and under the condition of toxic concentration the P24 antigen expression level has no great change.
Description
The invention belongs to the anti-AIDS drug field, relate in particular to TRICHOBITACIN and control application in the medicine of acquired immune deficiency syndrome (AIDS) in preparation.
Acquired immune deficiency syndrome (AIDS) (AIDS) is the deadly disease of the destruction body immune system that caused by human immunodeficiency virus (HIV).Owing to still there is not preventible effective vaccine at present, anti-AIDS medicine becomes the main means of control AIDS.The anti-AIDS medicine of current clinical usefulness is chemical synthetic drug, and often toxic side effect is big, easily produces shortcomings such as resistance.Seeking the new anti-AIDS medicine or the research of lead compound from conventional medicament and natural resource, is important research aspect and very active field in the current domestic and international new drug development.At least found that from natural resource tens kinds of compounds have the activity of anti-HIV.In addition, to being that (Ribosomeinactivating proteins, the active research of anti-AIDS RIP) has become the emphasis of research at present both at home and abroad for the ribosome inactivating protein of representative with the Trichosanthin.RIP is that a class acts on the eukaryotic cell rrna, arrestin matter synthetic toxalbumin, and (the Trichosanthin of representative Trichosanthin wherein, TCS) be a kind of alkaline single chain protein of forming by 247 amino acid that from cucurbitaceous plant snakegourd (Trichosanthes kirilowii) napiform root, extracts, molecular weight is 27KDa, pI is 9.4, does not contain halfcystine and glycosyl [Chow et al, 1990; Collin et al, 1990].TCS has RNA N-glycosidase activity [Zhang and Liu, 1992].TCS is one of new drug few in number of China oneself initiative.
The objective of the invention is based on above-mentioned prior art basis, a kind of new active ribosome inactivating protein-TRICHOBITACIN (Trichobitacin) with inhibition HIV is provided, its preparation method is provided simultaneously.
In order to realize purpose of the present invention, the invention provides following technical scheme:
TRICHOBITACIN, pressed the residue behind the juice for a kind of piece root and to have separated the strand ribosome inactivating protein that obtains from the snakegourd plant, molecular weight 27,228Da, iso-electric point 9.6, sugar content 0.7-0.9%, have RNA N-glycosidase activity, N-end and C-terminal amino acid are Aspartic Acid and L-Ala, and N-holds 38 amino acid whose sequences, except that 31 be the Isoleucine, the same with Trichosanthin.
The present invention also provides the method for preparing above-mentioned TRICHOBITACIN, gets snakegourd piece root, pressed residue behind the juice to soak with physiological saline after, use acetone precipitation, after the collecting precipitation lyophilize,, get the peak I that column chromatography for separation goes out and get final product with Sephadex G-50 or G-75 and CM-Sephadex C-50 purifying.Use high-efficient liquid phase chromatogram HPLC then, methods such as SDS-gel electrophoresis SDS-PAGE and HPCE HPCE are identified its purity, with the electronics place revolve-mass spectrum ES-MS measures its molecular weight, isoelectric focusing electrophoresis is measured iso-electric point, measures partial amino-acid series with automatic sequencer behind the enzymolysis.
The present invention also provides TRICHOBITACIN to control the application of acquired immune deficiency syndrome (AIDS) medicine as preparation.
The pharmacological results with TRICHOBITACIN of the present invention illustrates drug action of the present invention and beneficial effect below:
1, TRICHOBITACIN induces the C8166 cell to form plasmodial restraining effect to HIV-1:
On the flat Tissue Culture Plate in 96 holes, testing compound is carried out 5 times of doubling dilutions with perfect medium, totally seven extent of dilution, every hole 100 μ l establish 3 repeating holes, and the normal cell contrast is set simultaneously, the contrast of HIV cells infected.Every hole drips the C8166 cell 100 μ l of 3 * 105/ml, and every then hole adds the HIV-1 III B supernatant of 200 TCID50.Be that infection multiplicity is 0.007, the cumulative volume in every hole is 300 μ l.Put 37 ℃, cultivate in the 5%CO2 incubator.Infect the back and observed the influence that testing compound forms synplasm on the 3rd day.Under 100 times inverted microscope, choose 5 nonoverlapping visuals field, counting HIV-1 III B induces the plastidogenetic synplasm number of C8166.EC50 reaches 50% o'clock drug level for suppressing synplasm formation.CC50 is the drug level when 50% host cell is produced cytotoxicity, and selectivity index (SI) is the ratio of CC50/EC50.Table 1 TRICHOBITACIN suppresses HIV-1 III B and induces C8166 to form synplasm and to the cytotoxic effect of C8166
| Compound | ????EC50 ????(μg/ml) | ????CC50 ????(μg/ml) | ????SI |
| Chinese trichosanthes protein crude product (93P62 salt precipitation) Chinese trichosanthes protein crude product (XBP94P23) Chinese trichosanthes protein (XBP94P27) Chinese trichosanthes protein (93P10CM-I) Chinese trichosanthes protein (93P18CM-I) Chinese trichosanthes protein (94P70CM I) Chinese trichosanthes protein (94P70CM II) Chinese trichosanthes protein (94P73CM I) Chinese trichosanthes protein (94P75CM I) | ????0.01 ????0.0052 ????0.014 ????0.0118 ????0.0045 ????0.023 ????0.00273 ????0.005 ????0.001 | ????1.24 ????0.55 ????2.1 ????3.39 ????4.23 ????1.71 ????0.84 ????2.0 ????0.6 | ????124 ????105.8 ????150 ????287.3 ????940.0 ????74.4 ????307.7 ????400 ????600 |
As seen from Table 1, the purifying TRICHOBITACIN of TRICHOBITACIN crude product and different lot numbers all has remarkable vitro inhibition HIV-1 III B to induce the C8166 cell to form plasmodial effect.
2, TRICHOBITACIN is to the blocking effect of HIV cells infected fusion
Press (1987) such as Walker; The described method improvement of Johnson and Waker (1990) carries out.On 96 porocyte culture plates, with testing compound by 5 times of doubling dilutions, totally 4 extent of dilution, each extent of dilution is established 3 repeating holes, every hole 100 μ l.The control wells that does not contain testing compound is set simultaneously.Every hole drips 6 * 10
5The logarithmic phase C8166 cell 50 μ l and 2 * 10 of/ml
5The chronically infected H9 cell 50 μ l of the HIV-1 III B of/ml, promptly HIV-1 III B cells infected is 1: 3 with the ratio of the C8116 cell count that does not infect.Put 37 ℃, cultivate in the 5%CO2 incubator after 24 hours, under inverted microscope, merge the synplasm quantity that forms and infer the whether cohesive process of blocking virus and cell of compound by observation of cell."-" expression compound is not blocked the formation of cytogamy; "+" expression compound has been blocked the formation of cytogamy fully.
Table 2 TRICHOBITACIN is to HIV-1 III B and the influence of cell bonded
| Compound | Concentration (μ g/ml) | Merge and suppress |
| TRICHOBITACIN (93P10CM I) TRICHOBITACIN (93P18CM I) TRICHOBITACIN (94P70CM I) TRICHOBITACIN (94P73CM I) TRICHOBITACIN (94P75CN I) | ????13.2 ????13.8 ????6.0 ????4.35 ????5.85 | ??- ??- ??- ??- ??- |
After the CD4 receptors bind on the HIV-1 on cells infected surface and non-infected cells surface, can cause cytogamy to form synplasm.The medicine that acts on this target spot will be blocked the generation of merging.As seen from Table 2, TRICHOBITACIN all can not be blocked the fusion of cells infected.
3, TRICHOBITACIN is to the influence of virus replication in the HIV-1 acute infection cell
Improve slightly with reference to (1987) methods such as (1990) such as Lee-Huang and Walker.
Testing compound is diluted with perfect medium, establish 4 extent of dilution, each extent of dilution three hole, every hole 100 μ l.The control wells that does not contain compound is set simultaneously.Collect logarithmic phase C8166 cell suspension 50 μ l, promptly every hole contains 5 * 10
4Individual cell.Put 37 ℃, 5%CO
2Cultivate in the incubator, make compound and cell preact 60 minutes.Every hole adds the HIV-1 III B 50 μ l that contain 200 TCID50.Be that MOI is 0.004.Put 37 ℃, 5%CO
2Cultivated 72 hours in the incubator.The blue dye exclusion method counting of platform phenol with 0.8%, the calculating survivaling cell number.The collecting cell suspension, TGL-16C desk centrifuge 3000rpm, centrifugal 5 minutes.Collect culture supernatant and be used for ELISA mensuration P24 antigen levels.Reset and add 5%Triton X-100 solution 50 μ l deactivation and lytic viruses on per 450 μ l.Put-20 ℃ of preservations then, standby.With 50 μ l substratum re-suspended cell throw outs, cell suspension is added drop-wise in the hole of 8 hole slides, after the drying, fix 15 minutes with cold acetone, put-20 ℃ of preservations then.Be used for indirect IF staining and detect the HIV positive cell.
The effect that table 3 TRICHOBITACIN is duplicated acute infection HIV
| Compound concentration (μ g/ml) | Cell survivaling number (per-cent of experimental and control) | HIV antigen-positive cell decrement (%) | P24 antigen presentation inhibiting rate (%) |
| TRICHOBITACIN 5.0 (94P73CMI) 1.0 (lot number 1) 0.2 0.04 | ????41.9 ????81.4 ????102.3 ????99.7 | ????73?8 ????64.9 ????53.0 ????47.0 | ????86.3 ????81.3 ????58.2 ????54.8 |
| TRICHOBITACIN 5.0 (94P75CMI) 1.0 0.2 0.04 | ????51.2 ????74.4 ????76.7 ????79.1 | ????92.6 ????58.9 ????59.4 ????47.0 | ????84.1 ????80.1 ????61.7 ????52.6 |
Infect in the acute infection system of C8166 at HIV-1 III B, at first make compound pre-treatment C8166 cell 90 minutes, infect with HIV-1 III B then.Judge the influence that ribosome inactivating protein duplicates HIV by the variation that detects HIV antigen-positive cell percentage and HIV P24 antigenic expression.As seen from Table 3, TRICHOBITACIN all can suppress HIV-1 III B duplicating in acute infection C8166 cell significantly.The antigenic expression of HIV antigen-positive cell and P24 has certain dependency.
4, TRICHOBITACIN is to the antigenic influence of HIV-1 chronic infection cell expressing P24
Carry out with reference to (1992) methods such as Kinchington.
Testing compound is carried out doubling dilution with perfect medium on 96 hole microtest plates, each compound is established 4 extent of dilution, and each extent of dilution is established three holes, every hole 100 μ l.The control wells that does not contain compound is set simultaneously.Collect the 4th day the chronically infected H9 cell of HIV-1 III B in recovery back, transfer cell concn to 4 * 105/ml, every hole adds cells infected suspension 100 μ l.Be that every hole contains 4 * 104 cell count.Put 37 ℃, 5%CO
2Cultivated 96 hours in the incubator.The careful 150 μ l supernatants of drawing in every hole are used for ELISA and measure HIV P24 antigen levels after the 5%Triton X-100 deactivation.Measure the toxic action of compound with the MTT method to H9/HIV-1 III B cell.
Table 4 TRICHOBITACIN is to the influence of chronic infection cell expressing P24 antigen levels
| Compound | Concentration (μ g/ml) | Cell survivaling number (per-cent of experimental and control) | P24 antigenic expression (per-cent of experimental and control) |
| TRICHOBITACIN (94P73CMI) | ????5.0 ????1.0 ????0.2 ????0.04 | ????-0.5 ????13.5 ????43.3 ????88.2 | ????66.0 ????83.4 ????118.2 ????116.2 |
| TRICHOBITACIN (94P75CMI) | ????5.0 ????1.0 ????0.2 ????0.04 | ????0.2 ????9.0 ????26.5 ????68.8 | ????57.7 ????52.2 ????98.4 ????94.5 |
The ideal medicine should suppress acute infection and can suppress chronically infected HIV again and duplicate.The clinical of the overwhelming majority all can not reach this purpose with inverase now.As seen from Table 4, ribosome inactivating protein does not influence HIV-1 III B and duplicates in that chronic infection H9 is intracellular.
The beneficial effect that can draw TRICHOBITACIN of the present invention from above-mentioned experimental result is:
TRICHOBITACIN crude product and pure product all suppress HIV-1 significantly and induce the plasmodial formation of C8166; In acute infection, TRICHOBITACIN has suppressed the antigenic expression of HIV-1 P24 significantly, when compound concentration was 0.04 μ g/ml, 94P73CMI and 94P75CMI were respectively 54.8% and 52.6% (being that EC50 all is lower than 0.04 μ g/ml) to P24 antigen presentation inhibiting rate.The HIV-1 antigen-positive cell has reduced 47.0%; In chronic infection, TRICHOBITACIN does not have influence to duplicating of HIV-1 III B, even under toxic concentration, the P24 antigenic expression also changes not quite.Therefore, TRICHOBITACIN of the present invention is a kind of new ribosome inactivating protein with HIV (human immunodeficiency virus)-resistant activity.
Further specify essentiality content of the present invention below in conjunction with accompanying drawing with embodiment, but content of the present invention is not limited thereto.
Fig. 1 is the Sephadex G-75 column chromatography figure of TRICHOBITACIN of the present invention
Fig. 2 is the ion exchange column CM-Sephadex C-50 column chromatography figure of TRICHOBITACIN of the present invention
Embodiment one:
1. preparation TRICHOBITACIN: get snakegourd (Trichosanthes kirilowii Maxim (Cucurbitaceae) piece root, after having pressed residue behind the juice to soak with physiological saline, use acetone precipitation, after the collecting precipitation lyophilize, with molecular sieve Sephadex G-50 or G-75 and ion exchange column CM-Sephadex C-50 purifying, when ion-exchange chromatography, two peaks appear, and the peak I is TRICHOBITACIN (Trichobitacin).
Use HPLC then, SDS-PAE and and method such as HPCE identify its purity, measure its molecular weight with ES-MS, isoelectric focusing electrophoresis is measured iso-electric point, measures partial amino-acid series with automatic sequencer behind the enzymolysis.
2. the trypsin digestion of TRICHOBITACIN: get the 19mg TRICHOBITACIN, add 0.6ml 8mol/l urea, heating is 2 minutes in 100 ℃ of boiling water, adds 0.6ml distilled water and 0.6ml 0.4mol/l NH
4HCO
3, under agitation add the trypsinase aqueous solution 0.6ml that 0.3mg handled through TPCK, vibrate 37 ℃ of enzymolysis 24 hours.
3. the mensuration of the mixed peptide quality after the trypsin digestion TRICHOBITACIN: with the solution lyophilize behind the above-mentioned enzymolysis, measure the mixed peptide quality with MALD I-TOF-MS and FAB-MS respectively, MALD I-TOF-MS selects 2 respectively for use, 5-resorcylic acid (2,5-Dihydroxybenzoic acid, DHB) and alpha-cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamic acid CHCA) makes matrix, and FAB-MS makes matrix with glycerine.
4. TRICHOBITACIN is separated with HPLC through the peptide section of trypsin digestion: the TRICHOBITACIN enzymolysis is after 24 hours, and is centrifugal, and supernatant liquor is directly used high-efficient liquid phase chromatogram HPLC reversed-phase column (μ Bondapak C18,10mm * 30cm) separate; The precipitation part is washed several times through the N-methylmorpholine of pH8.1, and with the 65%TFA dissolving, centrifugal, clear liquid separates with HPLC, gets final product by following condition wash-out then.
Elutriant: A:0.1%TFA-H
2O B:0.08%TFA+80%CH
3CN
Gradient: time 0-43-50-55-58min
B％?0-65-100-100-0
Stream is saturating: 2mL/min detects wavelength: 230nm
5. the sequential analysis of partial peptide section: the peptide section after the HPLC separation and purification checks order by hand with automatic sequence instrument, DABITC/PITC double coupling method, and compares the identical peptide section with Trichosanthin of TRICHOBITACIN with mass spectroscopy, thereby determines the sequence of corresponding peptides.
TRICHOBITACIN by method for preparing, it is a kind of strand ribosome inactivating protein, molecular weight 27,228Da, iso-electric point 9.6, sugar content 0.7-0.9%, have RNA N-glycosidase activity, N-end and C-terminal amino acid are Aspartic Acid and L-Ala, and N-holds 38 amino acid whose sequences, except that 31 be the Isoleucine, the same with Trichosanthin.
Claims (3)
1, TRICHOBITACIN, it is characterized in that separating the residue after the piece root of snakegourd plant has been pressed juice a kind of strand ribosome inactivating protein that obtains, molecular weight 27,228Da, iso-electric point 9.6, sugar content 0.7-0.9%, have RNA N-glycosidase activity, N-end and C-terminal amino acid are Aspartic Acid and L-Ala, and N-holds 38 amino acid whose sequences, except that 31 be the Isoleucine, the same with Trichosanthin.
2, the method for preparing claim 1 TRICHOBITACIN, it is characterized in that getting snakegourd piece root, after having pressed residue behind the juice to soak with physiological saline, use acetone precipitation, after the collecting precipitation lyophilize, with Sephadex G-50 or G-75 and CM-Sephadex C-50 purifying, get the peak I that column chromatography for separation goes out and get final product.
3, claim 1 TRICHOBITACIN is controlled the application of acquired immune deficiency syndrome (AIDS) medicine as preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115693A CN1056383C (en) | 1997-11-29 | 1997-11-29 | Chinese trichosanthes protein, preparation method and use in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97115693A CN1056383C (en) | 1997-11-29 | 1997-11-29 | Chinese trichosanthes protein, preparation method and use in pharmacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1209435A true CN1209435A (en) | 1999-03-03 |
| CN1056383C CN1056383C (en) | 2000-09-13 |
Family
ID=5173375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97115693A Expired - Fee Related CN1056383C (en) | 1997-11-29 | 1997-11-29 | Chinese trichosanthes protein, preparation method and use in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056383C (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601680B1 (en) * | 1986-07-15 | 1990-06-29 | Sanofi Sa | PROTEIN SYNTHESIS INHIBITOR, ISOLATION METHOD, USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US4869903A (en) * | 1987-05-29 | 1989-09-26 | Genelabs Incorporated | Method of selectively inhibiting HIV |
-
1997
- 1997-11-29 CN CN97115693A patent/CN1056383C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1056383C (en) | 2000-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3588254T2 (en) | GAG antigen and its use for the detection of LAV infection, as well as in immunogenic compositions | |
| Miller et al. | Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein | |
| DE69311427T2 (en) | Synthetic polypeptides as inhibitors of HIV-1 | |
| DE3750812T2 (en) | Peptide composition and method for the detection of antibodies against HTLV-III. | |
| US5834429A (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens | |
| Brenneman et al. | Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp 120) of the human immunodeficiency virus | |
| WO1987007614A1 (en) | Small peptides which inhibit binding to t-4 receptors | |
| CN1056383C (en) | Chinese trichosanthes protein, preparation method and use in pharmacy | |
| DE69325943T3 (en) | Synthetic polypeptides of the hepatitis C virus, useful for the detection of the virus | |
| SE8701628D0 (en) | MEANS OF ANALYSIS MM | |
| DE69207200T2 (en) | IMMUNE TEST FOR SIMULTANEOUS DETECTION OF HIV-1, HIV-2, HTLV-I and HTLV-II ANTIBODIES | |
| EP0249394B1 (en) | Small peptides which inhibit binding to T-4 receptors and act as immunogens | |
| CN106397548A (en) | Polypeptide for inhibiting HIV infection, and pharmaceutical uses thereof | |
| EP0732339B1 (en) | Peptides of the HIV-gag protein, their preparation and use | |
| Baumann et al. | Structure-function studies on neurohormone D: activity of naturally-occurring hormone analogues | |
| WO1991018454A1 (en) | Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection | |
| CA2274853C (en) | Multiple branch peptide constructions | |
| WO2013075594A1 (en) | Artificially designed anti-hiv infection polypeptide, composition and use | |
| CN103159845B (en) | Method for synthetizing aviptadil | |
| CN1142181C (en) | Giant web bombinator polypeptide and its prepn. and pharmaceutical application | |
| KR100220531B1 (en) | Peptides that block human immunodeficiency virus infections and methods of use thereof | |
| AU604719B2 (en) | Small peptides which inhibit binding to t-4 receptors and act as immunogens | |
| Dettin et al. | Synthesis, characterization and conformational analysis of gp120‐derived synthetic peptides that specifically enhance HIV‐1 infectivity | |
| JP3725899B6 (en) | Multi-branched peptide constructs for use against HIV | |
| CN113754751B (en) | Novel sleep-promoting milk-derived active peptide CCL-2S, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |